Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Int J Mol Sci. 2021 Dec 30;23(1):392. doi: 10.3390/ijms23010392.
Prostate cancer is featured by its heterogeneous nature, which indicates a different prognosis. Castration-resistant prostate cancer (CRPC) is a hallmark of the treatment-refractory stage, and the median survival of patients is only within two years. Neuroendocrine prostate cancer (NEPC) is an aggressive variant that arises from de novo presentation of small cell carcinoma or treatment-related transformation with a median survival of 1-2 years from the time of diagnosis. The epigenetic regulators, such as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), have been proven involved in multiple pathologic mechanisms of CRPC and NEPC. LncRNAs can act as competing endogenous RNAs to sponge miRNAs that would inhibit the expression of their targets. After that, miRNAs interact with the 3' untranslated region (UTR) of target mRNAs to repress the step of translation. These interactions may modulate gene expression and influence cancer development and progression. Otherwise, epigenetic regulators and genetic mutation also promote neuroendocrine differentiation and cancer stem-like cell formation. This step may induce neuroendocrine prostate cancer development. This review aims to provide an integrated, synthesized overview under current evidence to elucidate the crosstalk of lncRNAs with miRNAs and their influence on castration resistance or neuroendocrine differentiation of prostate cancer. Notably, we also discuss the mechanisms of lncRNA-miRNA interaction in androgen receptor-independent prostate cancer, such as growth factors, oncogenic signaling pathways, cell cycle dysregulation, and cytokines or other transmembrane proteins. Conclusively, we underscore the potential of these communications as potential therapeutic targets in the future.
前列腺癌的特点是异质性,这表明预后不同。去势抵抗性前列腺癌(CRPC)是治疗耐药阶段的标志,患者的中位生存期仅为两年内。神经内分泌前列腺癌(NEPC)是一种侵袭性变异,源自小细胞癌的新发表现或与治疗相关的转化,从中位生存期诊断时的 1-2 年。表观遗传调节剂,如长非编码 RNA(lncRNA)和 microRNAs(miRNAs),已被证明参与 CRPC 和 NEPC 的多种病理机制。lncRNA 可以作为竞争性内源性 RNA 来吸收 miRNA,从而抑制其靶基因的表达。之后,miRNAs 与靶 mRNAs 的 3'非翻译区(UTR)相互作用,抑制翻译步骤。这些相互作用可能调节基因表达并影响癌症的发展和进展。此外,表观遗传调节剂和遗传突变也促进神经内分泌分化和癌症干细胞样细胞的形成。这一步可能会引发神经内分泌前列腺癌的发展。本综述旨在根据现有证据提供一个综合的、综合的概述,阐明 lncRNA 与 miRNA 的相互作用及其对前列腺癌去势抵抗或神经内分泌分化的影响。值得注意的是,我们还讨论了雄激素受体非依赖性前列腺癌中 lncRNA-miRNA 相互作用的机制,如生长因子、致癌信号通路、细胞周期失调以及细胞因子或其他跨膜蛋白。总之,我们强调了这些通讯作为未来潜在治疗靶点的潜力。